<DOC>
	<DOCNO>NCT01805960</DOCNO>
	<brief_summary>The purpose study test efficacy single injection Canakinumab AF recurrence within 6 month electrical cardioversion patient persistent AF .</brief_summary>
	<brief_title>Canakinumab Prevention Recurrences After Electrical Cardioversion : CONVERT-AF</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>EKGdocumented AF Undergoing electrical cardioversion Creactive protein ≥1.25mg/L Age ≥ 50 year , woman need postmenopausal Undergoing urgent cardioversion medical instability AF persistence cardioversion AF recurrence randomization Atrial flutter Severe renal failure ( creatinine clearance &lt; 30 ml/min ) Known active recurrent hepatic disorder ( include cirrhosis , hepatitis A , B C , Alanine transaminase/aspartate aminotransferase level &gt; 3x ULN total bilirubin &gt; 2x ULN ) History malignancy basal cell skin carcinoma Known intolerance allergic reaction canakinumab Use amiodarone within last 6 month Known HIV immune compromise state include neutropenia immunodeficiency History ongoing , chronic recurrent infectious disease History evidence active tuberculosis ( TB ) infection Visit 1 one risk factor tuberculosis limited exclusive : History follow : residence congregate setting ( e.g . jail prison , homeless shelter , chronic care facility ) , substance abuse ( e.g . injection noninjection ) , healthcare worker unprotected exposure patient high risk TB patient TB disease identification correct airborne precaution patient . Close contact ( i.e . share air space household enclose environment prolonged period ( day week , minute hour ) ) person active pulmonary TB disease within last 12 month . Evidence tuberculosis infection , Visit 1 , determine define local guidelines/ local medical practice ( see also determination tuberculosis status ) . If presence tuberculosis establish treatment ( accord local guideline ) must complete prior randomization . Completion treatment determine local TB guideline absence guideline follow demonstrated : TB treat adequately antibiotic , cure demonstrate , risk factor result TB exposure contract TB remove ( e.g . patient live anymore high TB exposure set ) . Patients systemic corticosteroid antiinflammatory drug nonsteroidal antiinflammatory drug Patients biological drug target immune system Acute coronary syndrome acute stroke within 3 month History heart failure hospitalization within 3 month Planned major surgery include plan coronary artery bypass graft Women childbearing potential Live vaccination within 3 month prior randomization visit ( visit 2 ) live vaccination plan trial . Life expectancy &lt; 1 year Inability comply study protocol Previously enrol CONVERTAF Patients receive investigational drug device within 30 day first visit . History alcohol and/or substance abuse could interfere conduct trial</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>